According to data compiled by Bloomberg, around 16.6 million shares of Biocon changed hands on the BSE in a single pre-market ...

In Biocon’s continuing effort to divest and Eris Lifesciences’ attempt to grow, the companies have expanded a previous agreement, with Bangalore-based generics giant Biocon selling Indian branded ...

True North is expected to be the seller in the transaction. The investment firm holds its Biocon stake through Activ Pine LLP ...

ICICI Prudential Mutual Fund emerged as the largest buyer, acquiring additional 74.03 lakh shares for Rs 285.02 crore. It was ...

Biocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell ...

Active Pine is likely to sell up to 1.66 crore Biocon shares, equivalent to 1% equity, through a block deal worth ₹638.4 ...

Pertuzumab is an antibody used to treat HER2-positive breast cancer and is currently not manufactured locally in Brazil.

Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue ...

Biocon Ltd, in the pharma sector, witnessed a 40% decline from the December 2020 high but shows signs of a bullish trend.

Biocon shares surged nearly 3% on Wednesday following a ₹635 crore block deal, where 1% equity changed hands at ₹385 per ...

Viatris Inc. , the company formed by the merger of Mylan and Pfizer Inc. unit Upjohn in 2020, said Monday it has reached an agreement to combine its biosimilars portfolio with Biocon Biologics Ltd.

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...